{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:10:07Z","timestamp":1789416607797,"version":"build-2803163510"},"reference-count":106,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.canlet.2011.06.016","type":"journal-article","created":{"date-parts":[[2011,7,23]],"date-time":"2011-07-23T06:22:09Z","timestamp":1311402129000},"page":"325-334","source":"Crossref","is-referenced-by-count":25,"title":["Targeting apoptosis proteins in hematological malignancies"],"prefix":"10.1016","volume":"332","author":[{"given":"Nathalie","family":"Droin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Gu\u00e9ry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na\u00efma","family":"Benikhlef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Solary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2011.06.016_b0005","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature05378","article-title":"Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1","volume":"445","author":"Ribeil","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2011.06.016_b0010","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1182\/blood-2009-03-208843","article-title":"Colony-stimulating factor-1-induced oscillations in phosphatidylinositol-3 kinase\/AKT are required for caspase activation in monocytes undergoing differentiation into macrophages","volume":"114","author":"Jacquel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0015","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1182\/blood-2002-03-0686","article-title":"Platelet formation is the consequence of caspase activation within megakaryocytes","volume":"100","author":"De Botton","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0020","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ng.103","article-title":"A mutation of human cytochrome c enhances the intrinsic apoptotic pathway but causes only thrombocytopenia","volume":"40","author":"Morison","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2011.06.016_b0025","doi-asserted-by":"crossref","first-page":"22135","DOI":"10.1074\/jbc.M414270200","article-title":"The canonical intrinsic mitochondrial death pathway has a non-apoptotic role in signaling lens cell differentiation","volume":"280","author":"Weber","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2011.06.016_b0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ni.1817","article-title":"Mechanisms maintaining peripheral tolerance","volume":"11","author":"Mueller","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2011.06.016_b0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000284367","article-title":"Neutrophil apoptosis: relevance to the innate immune response and inflammatory disease","volume":"2","author":"Fox","year":"2010","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.canlet.2011.06.016_b0040","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1182\/blood-2004-08-3166","article-title":"Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD","volume":"105","author":"Claessens","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0045","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2005-05-1989","article-title":"NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome","volume":"107","author":"Braun","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0050","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1074-7613(00)80587-7","article-title":"Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia","volume":"9","author":"Traver","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2011.06.016_b0055","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"MiR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2011.06.016_b0060","doi-asserted-by":"crossref","first-page":"29022","DOI":"10.1074\/jbc.M605116200","article-title":"The inhibitor of apoptosis protein fusion c-IAP2.MALT1 stimulates NF-kappaB activation independently of TRAF1 and TRAF2","volume":"281","author":"Varfolomeev","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2011.06.016_b0065","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1200\/JCO.2004.10.172","article-title":"Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma","volume":"22","author":"Schlette","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.06.016_b0070","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1517\/14728222.11.10.1299","article-title":"TRAIL in cancer therapy: present and future challenges","volume":"11","author":"M\u00e9rino","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.canlet.2011.06.016_b0075","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/79542","article-title":"Genetic analysis of chemoresistance in primary murine lymphomas","volume":"6","author":"Schmitt","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2011.06.016_b0080","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2005-05-2013","article-title":"Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes","volume":"106","author":"Rubio-Moscardo","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0085","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1093\/emboj\/cdf441","article-title":"Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but cannot functionally substitute caspase-8","volume":"21","author":"Sprick","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2011.06.016_b0090","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1002\/j.1460-2075.1995.tb00245.x","article-title":"Cytotoxicity-dependent APO-1 (Fas\/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor","volume":"22","author":"Kischkel","year":"1995","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2011.06.016_b0095","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1128\/MCB.00520-06","article-title":"Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2","volume":"26","author":"M\u00e9rino","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2011.06.016_b0100","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1158\/0008-5472.CAN-03-2219","article-title":"Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis","volume":"64","author":"Nesterov","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.06.016_b0105","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.emboj.7601551","article-title":"C-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis","volume":"26","author":"Nieminen","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2011.06.016_b0110","first-page":"123","article-title":"Playing the DISC: turning on TRAIL death receptor\u2013mediated apoptosis in cancer","volume":"1805","author":"Pennarun","year":"2010","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.canlet.2011.06.016_b0115","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.2009.25.4847","article-title":"Phase 1b study of dulanermin (recombinant human Apo2L\/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer","volume":"28","author":"Soria","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.06.016_b0120","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2009.25.1991","article-title":"Phase I dose-escalation study of recombinant human Apo2L\/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer","volume":"28","author":"Herbst","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.06.016_b0125","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/sj.bjc.6605987","article-title":"A phase 1b\/2 trial of mapatumumab in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma","volume":"103","author":"Younes","year":"2010","journal-title":"Br. J. Cancer."},{"key":"10.1016\/j.canlet.2011.06.016_b0130","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/annonc\/mdp292","article-title":"Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors","volume":"21","author":"Wakelee","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2011.06.016_b0135","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm1579","article-title":"Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia","volume":"13","author":"Mullican","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2011.06.016_b0140","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1158\/0008-5472.CAN-07-6278","article-title":"Mcl-1: a gateway to TRAIL sensitization","volume":"68","author":"Kim","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.06.016_b0145","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1158\/0008-5472.CAN-07-0598","article-title":"The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation","volume":"67","author":"Rosato","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.06.016_b0150","doi-asserted-by":"crossref","first-page":"29831","DOI":"10.1074\/jbc.M706110200","article-title":"Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization","volume":"282","author":"Meng","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2011.06.016_b0155","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood-2007-09-114314","article-title":"Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance","volume":"113","author":"Fakler","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0160","doi-asserted-by":"crossref","first-page":"8977","DOI":"10.1158\/0008-5472.CAN-09-2604","article-title":"A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia","volume":"69","author":"Loeder","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.06.016_b0165","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1182\/blood-2007-02-076075","article-title":"Cooperation of the proapoptotic receptor agonist rhApo2L\/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts","volume":"110","author":"Daniel","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0170","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-07-0680","article-title":"Augmented antitumor activity against B cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20","volume":"13","author":"Maddipatla","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2011.06.016_b0175","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2002-09-2975","article-title":"The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP","volume":"102","author":"Sayers","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0180","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1182\/blood-2002-10-3231","article-title":"Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2\/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2\/TRAIL","volume":"101","author":"Liu","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0185","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1158\/0008-5472.CAN-03-1656","article-title":"Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol","volume":"64","author":"Fulda","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.06.016_b0190","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.canlet.2010.04.029","article-title":"HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis","volume":"297","author":"Morales","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2011.06.016_b0195","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2007-10-116319","article-title":"Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells","volume":"112","author":"Fiskus","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0200","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.exphem.2008.07.012","article-title":"Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals","volume":"36","author":"Seal","year":"2008","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.canlet.2011.06.016_b0205","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.1038\/sj.onc.1205853","article-title":"Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia","volume":"21","author":"MacFarlane","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2011.06.016_b0210","doi-asserted-by":"crossref","first-page":"9199","DOI":"10.1074\/jbc.M305561200","article-title":"Identification and relevance of the CD95-binding domain in the N-terminal region of ezrin","volume":"279","author":"Lozupone","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2011.06.016_b0215","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/onc.2009.417","article-title":"Ezrin is a negative regulator of death receptor-induced apoptosis","volume":"29","author":"Kuo","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2011.06.016_b0220","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood-2005-12-007971","article-title":"Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells","volume":"108","author":"Menoret","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0225","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1200\/JCO.2009.22.5748","article-title":"5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen","volume":"27","author":"O\u2019Brien","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.06.016_b0230","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00063030-200721040-00004","article-title":"Locked nucleic acid oligonucleotides: the next generation of antisense agents?","volume":"21","author":"Gr\u00fcnweller","year":"2007","journal-title":"Biodrugs"},{"issue":"4","key":"10.1016\/j.canlet.2011.06.016_b0235","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/leu.2010.322","article-title":"The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia","volume":"25","author":"D\u00fcrig","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2011.06.016_b0240","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.4049\/jimmunol.178.10.6100","article-title":"Involvement of heat shock protein (Hsp)90 beta but not Hsp90 alpha in antiapoptotic effect of CpG-B oligodeoxynucleotide","volume":"178","author":"Kuo","year":"2007","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.canlet.2011.06.016_b0245","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nrd2658","article-title":"BCL-2 family antagonists for cancer therapy","volume":"7","author":"Lessene","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2011.06.016_b0250","doi-asserted-by":"crossref","first-page":"8731","DOI":"10.1158\/0008-5472.CAN-06-0367","article-title":"A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo","volume":"66","author":"Shoemaker","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.06.016_b0255","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2011.06.016_b0260","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell."},{"key":"10.1016\/j.canlet.2011.06.016_b0265","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.06.016_b0270","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed a nuclear cell death delimits platelet life span","volume":"128","author":"Mason","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2011.06.016_b0275","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1182\/blood-2009-07-233304","article-title":"Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1","volume":"115","author":"Yecies","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0280","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/jnci\/djn076","article-title":"Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation","volume":"100","author":"Kang","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2011.06.016_b0285","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1124\/mol.109.060780","article-title":"The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs","volume":"77","author":"High","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.canlet.2011.06.016_b0290","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1128\/MCB.01481-08","article-title":"Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1","volume":"29","author":"Chen","year":"2009","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2011.06.016_b0295","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1182\/blood-2008-05-156851","article-title":"Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors","volume":"113","author":"Whitecross","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0300","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1158\/0008-5472.CAN-10-3289","article-title":"Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737","volume":"71","author":"Wiegmans","year":"2011","journal-title":"Cancer Res."},{"issue":"40","key":"10.1016\/j.canlet.2011.06.016_b0305","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0606176103","article-title":"Bim and Bad mediate imatinib-induced killing of Bcr\/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic","volume":"103","author":"Kuroda","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.canlet.2011.06.016_b0310","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2141.2007.06899.x","article-title":"ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms","volume":"140","author":"Kuroda","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.canlet.2011.06.016_b0315","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/leu.2010.131","article-title":"Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin","volume":"24","author":"Li","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2011.06.016_b0320","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2007-12-130781","article-title":"The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies","volume":"112","author":"Paoluzzi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0325","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1172\/JCI38942","article-title":"Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction","volume":"120","author":"Samudio","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2011.06.016_b0330","doi-asserted-by":"crossref","first-page":"19512","DOI":"10.1073\/pnas.0709443104","article-title":"Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis","volume":"104","author":"Nguyen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2011.06.016_b0335","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2006-07-034173","article-title":"The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak","volume":"109","author":"P\u00e9rez-Gal\u00e1n","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0340","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1158\/1078-0432.CCR-08-0999","article-title":"A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies","volume":"14","author":"Schimmer","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.canlet.2011.06.016_b0345","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-07-1919","article-title":"Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax)","volume":"68","author":"Konopleva","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.06.016_b0350","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI39987","article-title":"Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance","volume":"120","author":"Bonapace","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2011.06.016_b0355","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood-2007-12-126946","article-title":"Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells","volume":"112","author":"Balakrishnan","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0360","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1158\/1535-7163.MCT-08-1050","article-title":"Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins","volume":"8","author":"Wei","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2011.06.016_b0365","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0092-8674(04)00162-X","article-title":"Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77\/TR3","volume":"116","author":"Lin","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2011.06.016_b0370","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccr.2008.09.002","article-title":"A short Nur77-derived peptide converts Bcl-2 from a protector to a killer","volume":"14","author":"Kolluri","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2011.06.016_b0375","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1182\/blood-2006-11-056879","article-title":"Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma","volume":"109","author":"Luciano","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0380","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/leu.2008.329","article-title":"Inhibitor of apoptosis proteins in hematological malignancies","volume":"23","author":"Fulda","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2011.06.016_b0385","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1126\/science.288.5467.874","article-title":"Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli","volume":"288","author":"Yang","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.canlet.2011.06.016_b0390","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/sj.cdd.4401069","article-title":"XIAP inhibition of caspase-3 preserves its association with the Apaf-1 apoptosome and prevents CD95- and Bax-induced apoptosis","volume":"9","author":"Bratton","year":"2002","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2011.06.016_b0395","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cell.2007.10.037","article-title":"IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis","volume":"131","author":"Vince","year":"2007","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.canlet.2011.06.016_b0400","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1097-2765(01)00341-0","article-title":"A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death","volume":"8","author":"Suzuki","year":"2001","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.canlet.2011.06.016_b0405","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1074\/jbc.M109784200","article-title":"The serine protease Omi\/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif","volume":"277","author":"Martins","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2011.06.016_b0410","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/35055027","article-title":"Identification of XAF1 as an antagonist of XIAP anti-caspase activity","volume":"2","author":"Liston","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2011.06.016_b0415","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1182\/blood-2005-08-3138","article-title":"Requirement of the human T-cell leukemia virus (HTLV-1) tax-stimulated HIAP-1 gene for the survival of transformed lymphocytes","volume":"107","author":"W\u00e4ldele","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0420","first-page":"1796","article-title":"Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukaemia\u2019s","volume":"6","author":"Tamm","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2011.06.016_b0425","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1038\/onc.2008.302","article-title":"IAP-targeted therapies for cancer","volume":"27","author":"LaCasse","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2011.06.016_b0430","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1158\/0008-5472.CAN-09-3892","article-title":"Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer","volume":"70","author":"Dineen","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.06.016_b0435","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nm735","article-title":"Smac agonists sensitize for Apo2L\/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo","volume":"8","author":"Fulda","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2011.06.016_b0440","doi-asserted-by":"crossref","first-page":"7729","DOI":"10.1158\/0008-5472.CAN-09-1794","article-title":"Down-regulation of c-FLIP enhances death of cancer cells by smac mimetic compound","volume":"69","author":"Cheung","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.06.016_b0445","doi-asserted-by":"crossref","first-page":"11936","DOI":"10.1073\/pnas.1005667107","article-title":"Overcoming cancer cell resistance to smac mimetic induced apoptosis by modulating cIAP-2 expression","volume":"107","author":"Petersen","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2011.06.016_b0450","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2008.19.5677","article-title":"Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer","volume":"27","author":"Dean","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.06.016_b0455","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1200\/JCO.2009.21.8172","article-title":"Phase I\/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia","volume":"27","author":"Schimmer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.06.016_b0460","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2004-08-3168","article-title":"Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells","volume":"105","author":"Carter","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.06.016_b0465","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10495-010-0545-1","article-title":"XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38-cells in a phase 1\/2 study of patients with relapsed\/refractory AML","volume":"16","author":"Carter","year":"2011","journal-title":"Apoptosis"},{"key":"10.1016\/j.canlet.2011.06.016_b0470","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.1158\/1078-0432.CCR-10-1932","article-title":"Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study","volume":"16","author":"Talbot","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2011.06.016_b0475","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1158\/1535-7163.MCT-08-0161","article-title":"SPC3042: a proapoptotic survivin inhibitor","volume":"7","author":"Hansen","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2011.06.016_b0480","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/15257771003597733","article-title":"Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide","volume":"29","author":"Sapra","year":"2010","journal-title":"Nucleos. Nucleot. Nucl. Acids"},{"key":"10.1016\/j.canlet.2011.06.016_b0485","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1021\/jm030420+","article-title":"Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database","volume":"47","author":"Nikolovska-Coleska","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2011.06.016_b0490","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1016\/j.bmcl.2006.08.072","article-title":"Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein","volume":"16","author":"Chen","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.canlet.2011.06.016_b0495","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/mol.106.028787","article-title":"Embelin, an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks nuclear factor-kappaB (NF-kappaB) signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products","volume":"71","author":"Ahn","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.canlet.2011.06.016_b0500","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1200\/JCO.2008.17.2064","article-title":"Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin","volume":"26","author":"Tolcher","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.06.016_b0505","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/jnci\/djj300","article-title":"Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors","volume":"98","author":"Gyurkocza","year":"2006","journal-title":"J. Natl. Cancer Instrum."},{"key":"10.1016\/j.canlet.2011.06.016_b0510","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00262-010-0845-x","article-title":"Antitumor cytotoxic T-cell response induced by a survivin peptide mimic","volume":"59","author":"Ciesielski","year":"2010","journal-title":"Cancer Immunol. Immun."},{"key":"10.1016\/j.canlet.2011.06.016_b0515","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1038\/leu.2008.172","article-title":"Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum","volume":"22","author":"Gyan","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2011.06.016_b0520","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4161\/cc.8.6.7906","article-title":"Tyrosine phosphorylation and CD95: a FAScinating switch","volume":"8","author":"Sancho-Martinez","year":"2009","journal-title":"Cell Cycle."},{"key":"10.1016\/j.canlet.2011.06.016_b0525","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nm1161","article-title":"Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells","volume":"11","author":"Nebbioso","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2011.06.016_b0530","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1158\/0008-5472.CAN-05-4563","article-title":"Cohen GM Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis","volume":"66","author":"Inoue","year":"2006","journal-title":"Cancer Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383511003612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383511003612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T23:42:16Z","timestamp":1712619736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383511003612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0304383511003612"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2011.06.016","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}